INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 43h ago
House PTR3h ago
SEC 13F3h ago
Robinhood Chain3h ago

Most active filers · 30d

  1. 01Kurtz George0B / 204S204 trades$51.20M
  2. 02SPSaba Capital Management, L.P.70B / 21S · 11 late91 trades$26.34M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04AJAllaire Jeremy0B / 50S50 trades$4.26M
  5. 05Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  6. 06SJSheena Jonathan0B / 43S43 trades$3.14M
  7. 07SLSpeiser Michael L0B / 35S35 trades$14.00M
  8. 08RARothblatt Martine A0B / 33S33 trades$5.50M
  9. 09RJRubinstein Julie0B / 33S33 trades$5.33M
  10. 10CECrimmins David Edward0B / 31S31 trades$723K

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  7. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  8. SELLULCCFrontier Group Holdings, Inc.Nov 5 – Nov 117 insiders$1.31M

Form 4 transactions

19,524 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
11
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$319K
711 sh
Nov 12, 2025
Page 474 of 489
← PrevNext →
Nov 14, 2025
traded Nov 12, 2025
+2d
SEC Form 4

Evidence

11
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$958K
2,132 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

11
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$891K
1,960 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

10
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$35K
400 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

9
KZ
Katz ZacharyGC and Head of Global Affairs
GRNDGrindr Inc.
Open-market sale · 10b5-1 plan
SELL$198K
13.8K sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

8
MH
Meyer Andrew HollmanChief Business Officer
JANXJanux Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$100K
3,333 sh
Nov 14, 2025Nov 14, 2025
traded Nov 14, 2025
+0dSEC Form 4

Evidence

8
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$204K
453 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

8
ND
Nguyen DianeEVP, Chief Legal Officer & GC
QBTSD-Wave Quantum Inc.
Open-market sale · 10b5-1 plan
SELL$65K
2,803 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

8
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$197K
430 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

5
CL
Charlton Rebecca LSVP, Controller & CAO
BKRBaker Hughes Co
Open-market sale · 10b5-1 plan
SELL$13K
278 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

5
AT
Arora TarunChief Accounting Officer
RNGRingCentral, Inc.
Open-market sale · 10b5-1 plan
SELL$24K
882 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

5
SD
Sroka DianaDirector
SOUNSOUNDHOUND AI, INC.
Open-market sale · 10b5-1 plan
SELL$17K
1,343 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
HX
Hao XinyanChief Operating Officer
GCTGigaCloud Technology Inc
Open-market sale · 10b5-1 plan
SELL$683K
21.4K sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$293K
654 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$400K
881 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
HX
Hao XinyanChief Operating Officer
GCTGigaCloud Technology Inc
Open-market sale · 10b5-1 plan
SELL$281K
8,568 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
HX
Hao XinyanChief Operating Officer
GCTGigaCloud Technology Inc
Open-market sale · 10b5-1 plan
SELL$768K
24.6K sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1000K
2,218 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$769K
1,702 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$665K
1,477 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
HX
Hao XinyanChief Operating Officer
GCTGigaCloud Technology Inc
Open-market sale · 10b5-1 plan
SELL$913K
30.0K sh
Nov 14, 2025Nov 14, 2025
traded Nov 14, 2025
+0dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$455K
1,013 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$724K
1,599 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

1
HX
Hao XinyanChief Operating Officer
GCTGigaCloud Technology Inc
Open-market sale · 10b5-1 plan
SELL$176K
5,446 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

1
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$119K
261 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

1
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$89K
195 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

57
LS
Levy Adam ScottCFO and Secretary
MLYSMineralys Therapeutics, Inc.
Open-market sale
SELL$1.53M
32.7K sh
Nov 11, 2025Nov 13, 2025
traded Nov 11, 2025
+2dSEC Form 4

Evidence

54
VE
Vivas EduardoDirector
APPAppLovin Corp
Open-market sale
SELL$12.58M
19.2K sh
Nov 10, 2025Nov 13, 2025
traded Nov 10, 2025
+3dSEC Form 4

Evidence

54
GM
Gold Alexander MDirector
MLYSMineralys Therapeutics, Inc.
Open-market sale
SELL$424K
10.0K sh
Nov 11, 2025Nov 13, 2025
traded Nov 11, 2025
+2dSEC Form 4

Evidence

54
VE
Vivas EduardoDirector
APPAppLovin Corp
Open-market sale
SELL$11.38M
17.5K sh
Nov 10, 2025Nov 13, 2025
traded Nov 10, 2025
+3dSEC Form 4

Evidence

54
VE
Vivas EduardoDirector
APPAppLovin Corp
Open-market sale
SELL$13.50M
20.7K sh
Nov 10, 2025Nov 13, 2025
traded Nov 10, 2025
+3dSEC Form 4

Evidence

54
VE
Vivas EduardoDirector
APPAppLovin Corp
Open-market sale
SELL$17.44M
26.8K sh
Nov 10, 2025Nov 13, 2025
traded Nov 10, 2025
+3dSEC Form 4

Evidence

54
KD
Karydas DaphneDirector
MLYSMineralys Therapeutics, Inc.
Open-market sale
SELL$463K
10.1K sh
Nov 13, 2025Nov 13, 2025
traded Nov 13, 2025
+0dSEC Form 4

Evidence

54
VE
Vivas EduardoDirector
APPAppLovin Corp
Open-market sale
SELL$20.10M
30.9K sh
Nov 10, 2025Nov 13, 2025
traded Nov 10, 2025
+3dSEC Form 4

Evidence

53
LS
Levy Adam ScottCFO and Secretary
MLYSMineralys Therapeutics, Inc.
Open-market sale
SELL$1.79M
38.9K sh
Nov 11, 2025Nov 13, 2025
traded Nov 11, 2025
+2dSEC Form 4

Evidence

51
VE
Vivas EduardoDirector
APPAppLovin Corp
Open-market sale
SELL$1.43M
2,201 sh
Nov 10, 2025Nov 13, 2025
traded Nov 10, 2025
+3dSEC Form 4

Evidence

51
VE
Vivas EduardoDirector
APPAppLovin Corp
Open-market sale
SELL$1.55M
2,399 sh
Nov 10, 2025Nov 13, 2025
traded Nov 10, 2025
+3dSEC Form 4

Evidence

51
KD
Karydas DaphneDirector
MLYSMineralys Therapeutics, Inc.
Open-market sale
SELL$226K
4,885 sh
Nov 13, 2025Nov 13, 2025
traded Nov 13, 2025
+0dSEC Form 4

Evidence

51
GM
Gold Alexander MDirector
MLYSMineralys Therapeutics, Inc.
Open-market sale
SELL$235K
5,000 sh
Nov 11, 2025Nov 13, 2025
traded Nov 11, 2025
+2dSEC Form 4

Evidence

51
VE
Vivas EduardoDirector
APPAppLovin Corp
Open-market sale
SELL$6.24M
9,619 sh
Nov 10, 2025Nov 13, 2025
traded Nov 10, 2025
+3dSEC Form 4

Evidence